Skip to content
    Clinical Trials

    Carfilzomib-Based Induction, ASCT, and Maintenance in Multiple Myeloma

    Bertuglia et alBlood

    Carfilzomib-Based Induction, ASCT, and Maintenance in Multiple Myeloma
    Long-term follow-up from the randomized phase 2 FORTE trial evaluated carfilzomib-based induction, consolidation, and maintenance strategies in transplant-eligible patients aged 65 years or younger with newly diagnosed multiple myeloma. Patients were initially randomized to receive carfilzomib, lenalidomide, and dexamethasone with autologous stem cell transplantation (KRd-ASCT), 12 cycles of KRd without transplantation (KRd12), or carfilzomib, cyclophosphamide, and dexamethasone with transplantation (KCd-ASCT). Following initial therapy, eligible patients underwent a second randomization to maintenance therapy with carfilzomib for 2 years plus lenalidomide until progression (KR) or lenalidomide monotherapy until progression (R). At an extended median follow-up of 99 months from initial randomization and 85 months from maintenance randomization, KRd-ASCT showed superior progression-free survival (PFS; median 98 months) compared to KRd12 (median 70 months; HR 0.71, p=0.027) and KCd-ASCT (median 67 months; HR 0.66, p=0.006). KRd-ASCT also achieved a significant benefit in PFS2 compared with KRd12 (HR 0.65, p=0.02) and KCd-ASCT (HR 0.68, p=0.04), as well as an overall survival (OS) advantage compared with KCd-ASCT (8-year OS: 76% vs 68%; HR 0.65, p=0.04). In the maintenance setting, KR significantly improved PFS compared to lenalidomide alone (HR 0.67, p=0.02), showing a time-dependent effect that persisted up to two years after carfilzomib cessation, though no differences in PFS2 or OS emerged. During active maintenance treatment, KR significantly increased the rate of measurable residual disease (MRD) conversion (sHR 0.47, p=0.03) and reduced MRD resurgence (sHR 0.53, p=0.001) relative to R, extending the median duration of MRD negativity to 50.5 months versus 38 months. KR significantly prolonged PFS in MRD-negative patients (HR 0.60, p=0.031), while MRD-positive patients derived benefit mainly during the active carfilzomib treatment phase (HR 0.46, p=0.05). Across the study, the cumulative incidence of second primary malignancies was 6%.

    Key Takeaways

    • KRd-ASCT significantly prolonged median progression-free survival to 98 months compared with 70 months for KRd12 (HR 0.71, p=0.027) and 67 months for KCd-ASCT (HR 0.66, p=0.006), while also yielding a superior 8-year overall survival over KCd-ASCT (76% vs 68%; HR 0.65, p=0.04).
    • KR maintenance significantly improved progression-free survival versus lenalidomide monotherapy (HR 0.67, p=0.02), reduced MRD resurgence (sHR 0.53, p=0.001), and extended median duration of MRD negativity (50.5 vs 38 months).